Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AV-101 (Inhaled Imatinib) in Pulmonary Arterial Hypertension
NCT05036135Phase 3Terminated
- Sponsor
- Aerovate Therapeutics
- Start
- Dec 2021
- Primary completion
- Aug 2024
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 26
01
Overview
A Phase 3 trial of AV-101 in pulmonary arterial hypertension (PAH), sponsored by Aerovate Therapeutics. Started Dec 2021; status: terminated.
02
Drugs
AV-101
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT05036135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05036135.